Program
Valproic Acid
Also written as “Divalproex Sodium”, “divalproex sodium” and “Sodium valproate”.
Its studies are mostly in Bipolar Disorder · Epilepsy · Migraine Disorders · Seizures · Schizophrenia, led by 11 companies.
Drug pageValproic Acid: every studyMany companies study it; this page follows only the 38 they lead. All 261 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 100 open or running | phase 3since May 15, 2003 | May 15, 2003 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 70 open or running | phase 1since Jan 25, 2010 | Jan 25, 2010 | none ahead |
| Sanofiits history only | 40 open or running | phase 4since Dec 9, 2005 | Dec 9, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 4since Aug 29, 2005 | Apr 9, 2004 | none ahead |
| Novartis | 30 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Desitin Arzneimittelits history only | 20 open or running | phase 1since Dec 21, 2023 | Dec 21, 2023 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Cerebral Therapeuticsits history only | 10 open or running | phase 2since Sep 3, 2016 | Sep 3, 2016 | none ahead |
| Hearthstone Alzheimer Careits history only | 10 open or running | phase 1since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Tecnoquimicasits history only | 10 open or running | phase 4since Apr 11, 2019 | Apr 11, 2019 | none ahead |
Also a collaborator on its studies: BioPharma Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 17, 2009First study: phase 1 study in SeizuresFirst studyNCT00864006 · 28 enrolled
- Jun 2, 20092 phase 1 studies in EpilepsyNCT00913874, NCT00913848
TargetBeta
“Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
All 3 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00913874Epilepsy | 1 | Completed | Oct 2005 | 30 |
| NCT00913848Epilepsy | 1 | Completed | Oct 2005 | 30 |
| NCT00864006Seizures | 1 | Completed | Oct 2006 | 28 |
How it is read
Names in the registry
- “Divalproex Sodium”, 10 entries
- “divalproex sodium”, 7 entries
- “Sodium valproate”, 3 entries
- “Valproic Acid”, 2 entries
- “Valproic Acid 500 MG”, 2 entries
Conditions, from the studies’ own filings
- Bipolar Disorder, 9 studies
- Epilepsy, 7 studies
- Migraine Disorders, 3 studies
- Seizures, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.